Reply to comment on: Hydroxyurea and pain history in relation to patient-reported outcomes using PROMIS® measures and the frequency of assessments in sickle cell disease patients.
Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia.|AFLAC Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia.
Carlton
C
Dampier
D000755:Anemia, Sickle Cell; D000986:Antisickling Agents; D006801:Humans; D006918:Hydroxyurea; D010146:Pain; D000071066:Patient Reported Outcome Measures
D000986:Antisickling Agents; D006918:Hydroxyurea